Description
Celanese Corporation had a very disappointing quarter as its business was impacted by macro-economic headwinds. The company failed to meet the revenue expectations as well as the earnings expectations of analysts. The profitability was below par despite the fact that during the quarter, raw material costs for acetyls significantly decreased. The good news is that this trend is continuing and might lead to some level of margin expansion in the future. The fourth quarter also saw a significant destruction of demand due to pricing, weather, destocking, and other factors. Among major updates, the company signed an agreement with Glaukos Corp. to supply its VitalDose Drug Delivery Platform for for use in Glaukos’ iDose TR. We give Celanese Corporation a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
